Drugs / Yellow Fever Vaccine
Yellow Fever Vaccine
also known as
Stamaril · YF-VAX · YFV · 17D · 17D-204 · Stamaril (yellow fever vaccine) · Stamaril vaccine · Yellow fever vaccine, Bio-Manguinhos · +5 more
Trials 24 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00254826 | Jun 2006 → Nov 2008 | parasitemia | Emory University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05859490 | Aug 2023 → Nov 2025 overdue | yellow fever | Oregon Health and Science University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04269265 | Jul 2020 → Oct 2023 | yellow fever | University of Minnesota | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05568953 | Sep 2022 → Oct 2025 | Japanese encephalitis, yellow fever | Singapore General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03116802 | Mar 2017 → Apr 2018 | yellow fever | Singapore General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01943305 | Oct 2013 → Jun 2015 | Japanese encephalitis, yellow fever | Singapore General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01262872 | Feb 2011 → Mar 2013 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00982137 | Jul 2004 → Apr 2005 | Japanese encephalitis, yellow fever | Sanofi | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06815835 | Apr 2025 → Mar 2026 overdue | measles, rubella, yellow fever | International Centre for Diarrhoeal Disease Research, Bangladesh | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06399003 | Jun → Sep 2024 | primary viral infectious disease | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 3 | NCT01436396 | Sep 2011 → Sep 2013 | Dengue hemorrhagic fever, yellow fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01426243 | Jul 2011 → Feb 2017 | HIV infectious disease, yellow fever | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT06148025 | Nov 2023 → Oct 2027 expected | — | South Australian Health and Medical Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT05374317 | Jun 2021 → Nov 2022 | yellow fever | US Army Medical Research Institute of Infectious Diseases | Completed | No outcome recorded |
| Phase 4 | NCT04059471 | Nov 2019 → Mar 2020 | yellow fever | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT04083430 | Oct 2019 → Feb 2025 | poisoning, yellow fever | University of Aarhus | Unknown | No outcome recorded |
| Phase 4 | NCT02991495 | Nov 2017 → Feb 2018 | yellow fever | Epicentre | Completed | No outcome recorded |
| Phase 4 | NCT02555072 | Jul 2016 → Jun 2026 overdue | yellow fever | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03368495 | Nov 2015 → Jun 2018 | — | Alba Maria Ropero | Completed | No outcome recorded |
| Phase 4 | NCT02286895 | Oct 2014 → Mar 2015 | Rotavirus infection | PATH | Completed | No outcome recorded |
| Phase 4 | NCT00694655 | May 2008 → Aug 2024 | yellow fever | Emory University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05450770 | Nov 2024 overdue | HIV infectious disease, yellow fever | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| — | NCT05901454 | Feb → Jul 2023 | yellow fever | Leiden University Medical Center | Unknown | No outcome recorded |
| — | NCT01765413 | Sep 2013 → Jan 2014 | — | University of Surrey | Completed | No outcome recorded |
Also used as a comparator or background therapy in 14 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04142086 Comparator | Jan 2020 → Jun 2021 | yellow fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06879327 Background | May 2025 → Sep 2027 expected | malaria | PATH | Recruiting | No outcome recorded |
| Phase 2 | NCT06213506 Background | Jan 2024 → Sep 2026 expected | salmonellosis | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05011123 Comparator | Oct 2021 → May 2022 overdue | yellow fever | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04942210 Comparator | Jul 2021 → Jun 2022 overdue | yellow fever | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00436007 Background | Apr 2007 → Sep 2008 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07103148 Comparator | Jul 2025 → Aug 2026 overdue | yellow fever | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT07002060 Comparator | May 2025 → Jan 2026 | yellow fever | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT05421611 Comparator | May 2023 → May 2024 | yellow fever | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05447377 Comparator | Sep 2022 → Jan 2024 | yellow fever | Serum Institute of India Pvt. Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02699099 Background | May 2017 → Mar 2018 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01345240 Background | Nov 2011 → Jan 2013 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01466387 Comparator | Nov 2011 → Apr 2012 | Japanese encephalitis, meningococcal meningitis, rabies, typhoid fever +1 | Novartis | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03430388 Comparator | Jan → Mar 2018 | Sjogren syndrome, Takayasu arteritis, granulomatosis with polyangiitis, juvenile dermatomyositis +6 | University of Sao Paulo General Hospital | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 40 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yellow Fever Vaccine | “MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.” NCT03368495 ↗ |
| Known as | 17D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05859490 ↗ |
| Known as | 17D-204 | “the Institut Pasteur de Dakar 17D-204 yellow fever vaccine” PMID 39970397 ↗ Feb 2025 |
| Known as | Stamaril | “Eligible participants will be randomized in 2 independent groups (9-24 months, 2-5 years) to receive 1 dose of either vYF or Stamaril or YF-VAX in a 2:1:1 ratio within each age group.” NCT07103148 ↗15“ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.” NCT00982137 ↗ “STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.” NCT04083430 ↗ “Participants receive one dose of 'Stamaril' yellow fever vaccine.” NCT01765413 ↗ “STAMARIL, 1 dose (0.5 ml)” NCT01943305 ↗ |
| Known as | Stamaril (yellow fever vaccine) | “Stamaril (yellow fever vaccine)” NCT05901454 ↗ |
| Known as | Stamaril vaccine | “Stamaril vaccine” NCT07103148 ↗ |
| Known as | Yellow fever vaccine, Bio-Manguinhos | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02991495 ↗ |
| Known as | Yellow fever vaccine, Chumakov Institute | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02991495 ↗ |
| Known as | Yellow fever vaccine, Institut Pasteur | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02991495 ↗ |
| Known as | YF vaccine (live) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07002060 ↗ |
| Known as | YF-17D | “The live yellow fever vaccine (YF-17D) offers a unique opportunity to study memory CD8(+) T cell differentiation in humans following an acute viral infection.” PMID 19933869 ↗ Dec 2009 |
| Known as | YF-VAX | “Healthy adults aged 18-60 years were randomised at a 1:1:1:1 ratio to receive one dose of vYF at 4, 5 or 6 Log CCID50 or YF-VAX (reference vaccine), administered subcutaneously...” PMID 39293214 ↗ Sep 20244“Eligible participants will be randomized in 2 independent groups (9-24 months, 2-5 years) to receive 1 dose of either vYF or Stamaril or YF-VAX in a 2:1:1 ratio within each age group.” NCT07103148 ↗ “YF-VAX®, Yellow Fever Vaccine, for subcutaneous use” NCT04269265 ↗ “the licensed yellow fever vaccine, YF-VAX” PMID 41950474 ↗ Apr 2026 |
| Known as | YF-VAX vaccine | “YF-VAX vaccine” NCT07103148 ↗ |
| Known as | YFV | “The live attenuated Yellow Fever Vaccine (YFV) as a safe and effective model for viral infection to understand human immune response to viral antigens.” NCT00694655 ↗1“Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).” NCT02286895 ↗ |
| Modality | Vaccine | “The yellow fever 17D vaccine YF-VAX® is manufactured in the United States.” NCT00254826 ↗ |
| Route | Intramuscular | “Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively.” NCT00436007 ↗ |